Immutep Limited

14/07/2025

Immutep Limited's CEO Marc Voigt appeared on ShareCafe’s latest episode of Table for Two, where he shared clinical trial updates across Immutep’s oncology and autoimmune programs.

Marc discusses the results from the TACTI-003 and INSIGHT-003 trials in head & neck cancer and in non-small cell lung cancer, as well as exciting progress on IMP761 - a first-in-class LAG-3 agonist antibody targeting autoimmune diseases.

Additionally, he highlights TACTI-004, Immutep's pivotal Phase 3 trial in non-small cell lung cancer, and outlines key upcoming milestones for the Company through year end 2025 and beyond.

Watch the full episode here:

Immutep (ASX:IMM) CEO Marc Voigt shares promising clinical trial updates across the company’s oncology and autoimmune programs.In head and neck cancer, the TACTI-003 trial has shown a median overall survival of 17.6 months—more than double the typical 7–8 months—and a much lower rate of seri...

23/06/2025

Immutep Limited announces positive initial efficacy data & continued favourable safety from first-in-human Phase I evaluating IMP761, a first-in-class agonist antibody. The substantial reduction in T cell activity at 0.9mg/kg dosing level highlights the potential efficacy of IMP761 in treating .

Dosing will continue at 2.5mg/kg and higher levels, with additional data to follow in 2H’CY2025.

Read more: http://bit.ly/3TA8fUF

02/06/2025

Immutep Limited is participating in the upcoming Jefferies Global Healthcare Conference in NYC. CEO Marc Voigt will present a company overview on Thurs, June 5th at 11:40am ET (US).

A live webcast and replay of the presentation will be available here: https://wsw.com/webcast/jeff319/immp/1860168

25/05/2025

Immutep Limited is pleased to report the investigator-initiated EFTISARC-NEO Phase II trial evaluating efti with and KEYTRUDA in (STS) has met its primary endpoint. STS is an orphan disease with high unmet medical need.

Detailed study results are planned for presentation at a medical conference later this year from the trial’s investigators at the Maria Sklodowska-Curie National Research Institute of Oncology.

Read more here https://bit.ly/4k48nYa

15/05/2025

Immutep Limited has reported excellent survival data from the investigator-initiated INSIGHT-003 trial aimed at treating advanced non-small cell lung cancer (NSCLC).

The trial reported a 60.8% response rate and 90.2% disease control rate in patients, according to RECIST 1.1. This data demonstrates significant improvement in response rate compared to historical controls and safety continues to be favorable.

Additional data from INSIGHT-003 is expected to be presented at a medical conference in 2025 and beyond.

Read more: https://bit.ly/4j70mk1

07/05/2025

Immutep Limited reported excellent survival data from the TACTI-003 Phase IIb trial: a median overall survival period of 17.6 months for head and neck cancer patients (PD-L1 CPS

22/01/2025

We're pleased to announce patient enrolment has been completed for the EFTISARC-NEO trial in soft tissue sarcoma.

The Phase II trial is evaluating Immutep Limited's efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) and is being conducted by the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw. Further data from the trial is expected in 2025.



Read the ASX announcement: https://bit.ly/3E1Zv5f

20/01/2025

Thank you to everyone who took the time to meet with Immutep Limited last week at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference.

It was a busy week for our team!

06/09/2024

Immutep Limited (ASX: IMM) is delighted to be joining the esteemed S&P/ASX 300 Index. Being part of the marks the Company's considerable growth and progress over the years, as well as enhancing its market visibility and supporting investor confidence.

Many thanks to our fantastic team and shareholders who share our excitement for the journey ahead for our LAG-3 therapeutics in cancer and autoimmune disease.

20/08/2024

Immutep Limited is excited to announce its late-breaking abstract has been accepted and selected as a Proffered Paper oral presentation at the 2024 ESMO - European Society for Medical Oncology Congress in Barcelona, Spain.

Claus Andrup Kristensen, MD, PhD, Head of Section for Thoracic and Head and Neck Oncology will present on Sunday 15 September at 10:25–10:35am CET.

Please click here to read full announcement: https://bit.ly/3XbAdJ9

19/08/2024

Immutep Limited CEO Marc Voigt talks to Finance News Network after the first patient was recently dosed in its first in human trial of IMP761.

IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases.

Safety data is anticipated by year-end and pharmacokinetics and pharmacodynamics data in first half CY2025.

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 19 August 2024 - CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is po...

22/07/2024

Immutep Limited is pleased to announce we have received positive feedback from the U.S. Food and Drug Administration regarding our planned TACTI-004 Phase III trial of efti in combination with KEYTRUDA®, MSD's anti-PD-1 therapy, and histology-based platinum doublet chemotherapy for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC), regardless of PD-L1 expression.

The TACTI-004 Phase III trial, which will enrol ~750 patients, is based on the positive efficacy and safety data in 1L NSCLC generated from the TACTI-002 Phase II and INSIGHT-003 trials.

Read the announcement: https://bit.ly/3WvCBK9